Reported Saturday, Lilly's Tirzepatide Outperformed Placebo In MASH Resolution, With More Than Half Of Patients Showing Fibrosis Improvement At 52 Weeks
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's tirzepatide showed significant efficacy in a phase 2 study for treating metabolic dysfunction-associated steatohepatitis (MASH), with over half of the patients showing fibrosis improvement at 52 weeks. The results were presented at the EASL Congress 2024 and published in The New England Journal of Medicine.
June 10, 2024 | 7:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's tirzepatide demonstrated significant efficacy in a phase 2 study for MASH, with over half of the patients showing fibrosis improvement at 52 weeks. This positive data could boost investor confidence and potentially drive the stock price up.
The positive results from the phase 2 study of tirzepatide in treating MASH, presented at a major medical conference and published in a reputable journal, are likely to boost investor confidence in Eli Lilly's pipeline. This could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100